Urokinase plasminogen activator system-Targeted delivery of nanobins as a novel ovarian cancer therapy

Molecular Cancer Therapeutics

Volumn 12, Issue 12, 2013, Pages 2628-2639

  Zhang, Yilin ^a   Kenny, Hilary A ^a   Swindell, Elden P ^b,c   Mitra, Anirban K ^a   Hankins, Patrick L ^b,d   Ahn, Richard W ^b,d   Gwin, Katja ^a   Mazar, Andrew P ^b,e,f   O'Halloran, Thomas V ^b,d,f   Lengyel, Ernst ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Chemistry of Life Processes Institute   (United States)

^c Chemical and Biological Engineering   (United States)

^d Departments of Chemistry   (United States)

^e Departments of Molecular Biosciences   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ANTIBODY; ARSENIC TRIOXIDE; CASPASE; LIPOSOME; PROTEINASE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; UROKINASE; UROKINASE PLASMINOGEN ACTIVATOR ANTIBODY; UROKINASE RECEPTOR;

ANTIGEN BINDING; APOPTOSIS; ARTICLE; COCULTURE; CONFOCAL MICROSCOPY; CONJUGATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; EX VIVO STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MASS SPECTROMETRY; MESOTHELIUM CELL; MOLECULARLY TARGETED THERAPY; OMENTUM; OVARY CANCER; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; STEM CELL; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ARSENATES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LIPOSOMES; MICE; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; PROTEIN BINDING; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; TUMOR BURDEN; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890456478     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0204     Document Type: Article

References (44)

1. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011;61:183-203
2. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol 2010;177:1053-64
3. Vaughn S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev 2011;11:719-25
4. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003;42:419-36
5. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: A randomized phase 3 study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-22
6. Vaage J, Donovan D, Mayhew E, Abra R, Huang A. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer 1993;72:3671-5
7. Kim BY, Rutka JT, Chan WC. Nanomedicine. N Engl J Med 2010;363: 2434-43
8. Zamboni WC, Torchilin V, Patri AK, Hrkach J, Stern S, Lee R, et al. Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. Clin Cancer Res 2012;18:3229-41
9. Kirpotin DB,Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006;66:6732-40
10. Salva R, Taratula O, Garbuzenko O, Minko T. Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. J Control Release 2011;153:16-22
11. Xiao K, Li Y, Lee JS, Gonik AM, Dong T, Fung G, et al. "OA02" peptide facilitates the precise targeting of paclitaxel-loaded micellar nanoparticles to ovarian cancer in vivo. Cancer Res 2012;72:2100-10
12. Chen H, Ahn R, Van den Bossche J, Thompson DH, O'Halloran TV. Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide. Mol Cancer Ther 2009;8:1955-63
13. Kirpotin DB, Noble CO, Hayes ME, Huang Z, Kornaga T, Zhou Y, et al. Building and characterizing antibody-targeted lipidic nanotherapeutics. Methods Enzym 2012;502:139-66
14. Ahn RW,Chen F, Chen H, Stern ST, Clogston JD, Patri AK, et al.Anovel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer. Clin Cancer Res 2010;16:3607-17
15. Chen H, MacDonald R, Li S, Krett NL, Rosen ST, O'Halloran TV. Lipid encapsulation of arsenic trioxide attenuates cytotoxicity and allows for controlled anticancer drug release. J Am Chem Soc 2006;128: 13348-9
16. Uslu R, Sanli UA, Sezgin C, Karabulut B, Terzioglu E, Omay SB, et al. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res 2000;6:4957-64
17. 3) inhibits peritoneal invasion of ovarian carcinoma cells in vitro and in vivo. Gynecol Oncol 2006;103:199-206
18. Mazar AP, Ahn RW, O'Halloran TV. Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic. Curr Pharm Des 2011;17:1970-8
19. Mazar AP. Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res 2008;14:5649-55
20. Kenny HA, Leonhardt P, Ladanyi A, Yamada SD, Montag AG, Im HK, et al. Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res 2011;17:459-71
21. Cubellis M, Wun T, Blasi F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 1990;9:1079-85
22. Conese M, Nykjaer A, Petersen CM, Andreasen PA, Gliemann J, Christensen EI, et al. α-2 Macroglobulin receptor/LDL receptor-related protein (Lrp)-dependent internalization of the urokinase receptor. J Cell Biol 1995;131:1609-22
23. Kaur S, Kenny HA, Jagadeeswaran S, Zillhardt M, Montag AG, Kistner E, et al. b3-Integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am J Pathol 2009;175:2184-96
24. Hong V, Presolski SI, Ma C, Finn MG. Analysis and optimization of copper-catalyzed azide-alkkyne cycloaddition for bioconjugation. Angewandte Chem 2009;121:10063-7
25. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt M, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 2011;17:1498-503
26. Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny HA, Salgia R, et al. C-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 2007;67:1670-80
27. Kenny HA, Krausz T, Yamada SD, Lengyel E. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extracellular matrices on adhesion and invasion of ovarian cancer cells. Int J Cancer 2007;121:1463-72
28. Mitra AK, Zillhardt M, Hua YJ, Tiwari P, Murmann A, Peter ME, et al. MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov 2012;2:1100-8
29. The Cancer Genome Atlas Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15
30. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer S, Arman B, et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401-4
31. Al-Hassan NN, Behzadian A, Caldwell R, Ivanova VS, Syed V, Motamed K, et al. Differential roles of uPAR in peritoneal ovarian carcinomatosis. Neoplasia 2012;14:259-70
32. Vermeer W, Norde W. The thermal stability of immunoglobulin: unfolding and aggregation of a muti-domain protein. Biophys J 2000;78: 394-404
33. 2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with AP02/TRAIL. Blood 2003;101:4078-87
34. Miller WH, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002;62:3893-903
35. Chenna V, Hu C, Pramanik D, Aftab BT, Karikari C, Campbell NR, et al. A polymeric nanoparticle encapsulated small-molecule inhibitor of hedgehog signaling (nanoHHI) bypasses secondary mutational resistance to smoothened antagonists. Mol Cancer Ther 2011;11:165-73
36. Landen CN, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, et al. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 2010;9:3186-99
37. Dadashzadeh S, Mirahmadi N, Babaei MH, Vali AM. Peritoneal retention of liposomes:Eeffects of lipid composition, PEG coating and lipsome charge. J Control Release 2010;148:177-86
38. Armstrong DK, Bundy B, Wenzel L, Huang H, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;353:34-43
39. Yang L, Peng XH, Wang X, Cao Z, Ni C, Karna P, et al. Receptortargeted nanoparticles for in vivo imaging of breast cancer. Clin Cancer Res 2009;15:4722-32
40. Barlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A 2007;104:15549-54
41. Murphy EA, Majeti BK, Mukhavaram R, Acevedo LM, Barnes LA, Cheresh D. Targeted nanogels: A versatile platform for drug delivery to tumors. Mol Cancer Ther 2011;10:972-82
42. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, et al. Complete remission after treatment of acute pro-myelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339:1341-8
43. Ahmet AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010;221:49-56
44. MacFarlane RG, Pilling J. Fibrinolytic activity of normal urine. Nature 1947;159:779